Amgen Inc.

Paul John Dransfield

Jonathan B Houze

Vatee Pattaropong

Zhihua Ma

Zice Fu

Julio Cesar Medina

Su-Jen Lai

Julie Anne Heath

Nobuko Nishimura

David John Kopecky

Mikkel V Debenedetto

Gayathri Swaminath

Xiaohui Du

Xiaoqi Chen

Xiaodong Wang

Richard V Connors

Steven H Olson

Ning Chen

Jeffrey Thomas Mihalic

Alan C Cheng

Yinhong Chen

Aarif Yusuf Khakoo

Wen-Chen Yeh

Jeffrey Deignan

Kevin Chao Yang

Matthew R Kaller

Ted Charles Judd

Daniel B Horne

James S Harvey

Simon J Hedley

Lawrence R McGee

Frank Kayser

Robert P Farrell

Jiwen Liu

Yingcai Wang

Todd J Kohn

Marc Vimolratana

Wang Shen

Sean P Brown

Michael J Schmitt

SuJen Lai

Liusheng Zhu

Ming Yu

Rajiv Sharma

Zhongyu Wang

Jinqian Liu

XianYun Jiao

Ankit Sharma

Hilary Plake Beck

Charles Kreiman

An-Rong Li

Lars V Heumann

Xian Yun Jiao

Malgorzata Wanska

Philip Dean Ramsden

Matthew Irvine Brown

Jian Luo

Timothy David Cushing

Michael G Johnson

Felix Gonzalez Lopez De Turiso

Kevin Yang

Jie Zhang

David C Moebius

YuMei Xiong

Yongli Su

Margrit Schwarz

Yong-Jae Kim

Jeffrey D Reagan

Qiong Cao

Jillian L Simard

Daniel Lin

Li Yang

Lawrence R Mcgee

Jeffrey T Mihalic

Julio C Medina

Jonathan Houze

Ted C Judd

Sujen Lai

Matthew Brown

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula I, pharmaceutically acceptable salts thereof, tautomers thereof, pharmaceutically acceptable salts of the tautomers, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein. 

Fused triazole agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor. Such compounds include those selected from 

Bromotriazole intermediates

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Growing community of inventors

Arlington, MA, United States of America

Paul John Dransfield